Recently Viewed
Clear AllQuality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,960 Cr
Revenue (TTM)
₹766 Cr
Net Profit (TTM)
₹80 Cr
ROE
9.2 %
ROCE
12.4 %
P/E Ratio
24.4
P/B Ratio
2.1
Industry P/E
43.12
EV/EBITDA
9.1
Div. Yield
0.5 %
Debt to Equity
0.2
Book Value
₹289.2
EPS
₹24.8
Face value
5
Shares outstanding
32,438,672
CFO
₹583.62 Cr
EBITDA
₹559.32 Cr
Net Profit
₹284.73 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Krsnaa Diagnostics
| -16.1 | -9.8 | -16.0 | -15.5 | 15.2 | -- | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Krsnaa Diagnostics
| -20.8 | 25.5 | 53.2 | -37.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Krsnaa Diagnostics
|
605.1 | 1,960.4 | 766.3 | 80.5 | 15.7 | 8.9 | 24.4 | 2.1 |
| 251.9 | 616.0 | 230.1 | 23.5 | -- | 28.7 | 27.8 | 4.8 | |
| 1,346.9 | 22,583.1 | 2,662.8 | 533.1 | 22.9 | 24.1 | 42.7 | 8.8 | |
| 672.0 | 26,925.4 | 3,626.9 | 315.0 | 15.0 | 13.3 | 89.5 | 11.6 | |
| 1,867.9 | 9,674.7 | 1,566.5 | 169.5 | 14.8 | 12.7 | 57.5 | 6.6 | |
| 554.0 | 5,553.4 | 755.8 | 67.1 | -- | 13.8 | 82.8 | 5.7 | |
| 285.6 | 929.3 | 1,231.3 | 29.1 | -4.7 | 4 | 35.7 | 1.4 | |
| 263.9 | 1,360.9 | 294.1 | 32.4 | 17.4 | 15.1 | 40.9 | 5.7 | |
| 372.7 | 5,934.5 | 792.3 | 135.5 | 23.5 | 26.4 | 43.1 | 8.9 | |
| 938.2 | 9,082.5 | 768.1 | 159.9 | 29.2 | 19.3 | 57 | 10.0 |
IPO update: Krsnaa Diagnostics
3 min read•By Udhayaprakash
Krsnaa Diagnostics: IPO analysis
6 min read•By Arul Selvan
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers diagnostic services, including radiology services, such as MRI and advanced imaging; pathology services, such as laboratory services, and home collection and preventive... health services; and teleradiology services, such as retail diagnostics services. The company also provides other diagnostics services, such as ophthalmic tests, mammography, dental imaging, stress test, DEXA scan, and bone mineral density. It serves its services to public and private hospitals, medical colleges, and community health centers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India. Read more
Incorporated
2010
Chairman
Rajendra Mutha
Managing Director
Yash Mutha
Headquarters
Pune, Maharashtra
Website
Looking for more details about Krsnaa Diagnostics Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
The share price of Krsnaa Diagnostics Ltd is ₹605.10 (NSE) and ₹604.35 (BSE) as of 18-Mar-2026 IST. Krsnaa Diagnostics Ltd has given a return of 15.2% in the last 3 years.
The P/E ratio of Krsnaa Diagnostics Ltd is 24.39 times as on 18-Mar-2026, a 43 discount to its peers’ median range of 43.12 times.
The P/B ratio of Krsnaa Diagnostics Ltd is 2.09 times as on 18-Mar-2026, a 72 discount to its peers’ median range of 7.40 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.68
|
2.89
|
|
2024
|
34.93
|
2.46
|
|
2023
|
23.26
|
1.96
|
|
2022
|
22.29
|
2.23
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Krsnaa Diagnostics Ltd are Rs 894.40 and Rs 579.15 as of 19-Mar-2026.
Krsnaa Diagnostics Ltd has a market capitalisation of ₹ 1,960 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Krsnaa Diagnostics Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.